Clinical ink is a leading brand that specializes in providing innovative technology solutions for clinical trials. Our mission is to revolutionize the way sponsors, CROs, and researchers conduct their studies, enhancing efficiency and accuracy in data collection. We offer a comprehensive suite of eCOA (electronic Clinical Outcome Assessments) solutions, including Direct Data Capture, eConsent, and our groundbreaking eLAS® Suite.

These solutions integrate mobile devices, sensors, and wearables, transforming the way clinical trials are conducted and enabling remote patient monitoring. Clinical ink is dedicated to supporting decentralized clinical trials, patient engagement, and the advancement of various therapeutic areas such as diabetes, immunology, infectious diseases, and neurology. Our insights and expertise provide valuable resources for researchers and industry professionals alike.

As part of our commitment to innovation, we are proud to announce the appointment of Andrew Kraus as Chief Technology Officer. With Andrew's leadership, we are expanding our technology portfolio to further improve and streamline clinical trial processes. Discover the future of clinical trials with Clinical ink and request more information today